8:15 am Digital Networking Room Opens
8:45 am Chair’s Opening Remarks
Cutting-Edge Claudin Development: Showcasing Development of Novel Claudin Therapies Revolutionizing Oncology
9:00 am Zolbetuximab: Clinical Development of Claudin 18.2 Monoclonal Antibodies
Synopsis
- Exploring Zolbetuximab, a monoclonal antibody targeting claudin 18.2, and its application in treating metastatic gastric cancer
- Reviewing a detailed presentation on clinical trial outcomes, including efficacy, safety, and the impact on progression-free survival and overall survival rates
- Integrating Zolbetuximab into standard treatment regimens and its potential for combination with other therapeutic modalities
9:30 am Preclinical Showcase of XmAb541 in Claudin 6-Targeted Bispecific Antibody Therapy
Synopsis
- Showcasing Xencor’s XmAb541, a CLDN6 x CD3 bispecific antibody, designed to engage T cells and selectively kill claudin 6 expressing tumor cells while sparing normal tissues
10:00 am Virtual Introductions & Networking Session
Synopsis
Head over to the Networking Zone to connect with the remainder of your fellow speakers and attendees at the Claudin-Targeted Therapies Summit. Visit the different rooms to introduce yourself to your claudin peers, and debate the most pressing challenges and opportunities facing this emerging oncology target
10:30 am Coffee Break
Clinical Modality Advancements & Biological Insights in Claudin-Targeted Cancer Therapies
11:00 am Panel Discussion: Clinical Advancements in Claudin-Targeted ADCs, Bispecifics, & CAR-T Therapies
Synopsis
- Deep diving into the latest advancements and clinical outcomes of ADCs targeting Claudin 18.2 and Claudin 6, with a focus on engineering, payload optimization, and toxicity management specific to claudin targets
- Examining the role and efficacy of bispecific antibodies in enhancing the immune response against claudin-expressing tumors, supported by insights from preclinical and clinical data
- Analyzing the development, challenges, and clinical trial results of CAR-T therapies for claudin-targeted treatments, emphasizing construct design, manufacturing hurdles, and strategies for managing associated toxicities
11:45 am Understanding the Synergistic Potential of Combining Claudin 18.2-Targeted Therapies with Immunotherapies
Synopsis
- Examining the rationale for combining Claudin 18.2-targeted therapies with immunotherapies, such as checkpoint inhibitors, to enhance anti-tumor immune responses
- Exploring preclinical and clinical data supporting combination strategies, focusing on the synergistic effects and improved therapeutic outcomes
- Reviewing the impact of combination therapies on efficacy and safety profiles, including strategies to manage immune-related adverse events
12:15 pm Lunch & Networking
Exploring Innovations & Applications in Claudin 6-Targeted Cancer Therapies
1:15 pm Identification & Preclinical Characterization of CTIM-76, a CLDN6 x CD3 Bispecific Antibody
Synopsis
Isolation of CLDN6 antibodies with exquisite specificity for CLDN6 over other members of the CLDN family
Molecular engineering and in vitro characterization of CTIM-76
Preclinical data supporting CTIM-76 entry into clinical trials for ovarian cancer and other advanced solid tumors
1:45 pm Development & Application of Claudin 6-Targeted Therapies in Ovarian, Testicular, & Endometrial Cancers
Synopsis
- Focusing on Claudin 6 expression in ovarian, testicular, and endometrial cancers and the potential for targeted therapies in these indications
- Uncovering the development and clinical potential of ADCs targeting Claudin 6, including preclinical efficacy and safety data
- Highlighting the safety profile and patient selection criteria for Claudin 6-targeted therapies, including strategies to minimize off-target effects
2:15 pm Claudin 1: in Cancer & Organ Fibrosis
Synopsis
- Examining the role of Claudin 1 in cancer and organ fibrosis
- Discussing the pre-clinical development and the therapeutic potential of monoclonal antibodies and ADCs targeting Claudin 1
- Addressing the phase I development for Claudin 1-targeted therapies